Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Prevention of mother-to-child transmission news

Show

From To
Elvitegravir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1

Pharmacokinetic data indicate exposure of elvitegravir boosted with cobicistat (Genvoya, Stribild) is lower during the second and third trimesters of pregnancy than postpartum. Low elvitegravir exposure may be associated with an increased risk of treatment failure and an increased risk of HIV-1 transmission to the unborn child, and therefore elvitegravir/cobicistat should not be used during pregnancy.

Published
17 April 2019
From
Medicines and Healthcare products Regulatory Agency
Avoiding Dolutegravir in Young Women With HIV: Time for a Rethink?

Total deaths for women with HIV and their children are projected to be lower with dolutegravir-based (Tivicay) antiretroviral therapy (ART) versus efavirenz-based (Sustiva) ART, a model-based analysis found.

Published
05 April 2019
From
MedPage Today
'Vast majority' of elevated viral load episodes in pregnant women caused by non-adherence

Non-adherence to ART — and not pretreatment drug-resistant mutations — explain the “vast majority” of elevated viral load episodes in women initiating ART during pregnancy, according to results from a study conducted in South Africa.

Published
02 April 2019
From
Healio
HIV antibody VRC01LS safe prevention strategy for infants

Subcutaneous doses of a broadly neutralizing monoclonal antibody, known as VRC01LS, given at birth and 12 weeks were well-tolerated by HIV-exposed infants, according to the results of an open-label safety and pharmacokinetic study presented at the Conference on Retroviruses and Opportunistic Infections. Researchers are studying VRC01LS in combination with ART to prevent HIV infection in neonates.

Published
12 March 2019
From
Healio
Tshepiso study: Preventive TB therapy not associated with poor pregnancy outcomes

Initiating isoniazid preventive therapy for tuberculosis during pregnancy is not associated with a higher rate of poor maternal or infant outcomes, according to observational results from the Tshepiso study presented at CROI.

Published
12 March 2019
From
Healio
CROI 2019: Thailand’s strides spanned HIV treatment, prevention and research

he first HIV vaccine trials to yield signs of hope happened here. Thailand was also the first Asian country to eliminate mother-to-child transmission of HIV. Now, Thailand has achieved the first part of UNAIDS’ 90-90-90 targets: 98 percent of people infected with HIV know their status.

Published
06 March 2019
From
Science Speaks
South Africa urgently needs an antiretroviral pregnancy registry

With the dolutegravir roll-out around the corner, the time is now ripe for patients and activists to demand a prospective pregnancy registry for the whole of South Africa. Whether it is a new endeavour or piggy-backs on international efforts is a matter for debate, but it is the only way we can answer the question of dolutegravir’s safety with the minimum number of women being exposed to the drug. It’s the least that patients deserve.

Published
29 January 2019
From
Spotlight
As A Strategy for HIV Prevention, Disabling the CCR5 Gene in Embryos Implanted in HIV-Negative Mothers Makes Zero Sense

Here are a bunch of things we know about HIV prevention. You’ll note that nowhere on this list is anything about preventing HIV in babies born to women who don’t have the virus to begin with — because the babies are not at risk, even if the mother’s male sexual partner has HIV.

Published
03 December 2018
From
NEJM Journal Watch
Gene editing won’t help the fight against HIV, understanding one’s risk and prevention options will

Andrew Chidgey says HIV positive men and women can already have HIV negative babies through the use of medication and some well-recognised precautions. This negates the need for gene editing to prevent transmission of HIV and raises ethical questions about a Chinese scientist’s recently announced research.

Published
01 December 2018
From
South China Morning Post
Children, HIV and AIDS: The world today and in 2030

The world pledged to end AIDS by 2030. While we have seen remarkable progress in the past decade among children aged 0-9 years, adolescents have been left behind in HIV prevention efforts. A staggering 360,000 adolescents are projected to die of AIDS-related diseases between 2018 and 2030 without additional investment in HIV prevention, testing and treatment programs.

Published
30 November 2018
From
UNICEF
← First12345...25Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.